Patents by Inventor Elizabeth Hood
Elizabeth Hood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210299272Abstract: Compositions comprising a dual-targeted nanoparticle having a first targeting moiety and a second targeting moiety, wherein said first targeting moiety is a red blood cell (RBC)-targeting moiety are provided. In certain embodiment, the nanoparticles are bound to RBCs ex vivo. Also provided are methods of delivering selected drugs to target organs using these compositions for treatment of disease or for diagnostic imaging.Type: ApplicationFiled: March 31, 2021Publication date: September 30, 2021Inventors: Vladimir Muzykantov, Jacob S. Brenner, Carlos H. Villa, Laura Ferguson, Elizabeth Hood
-
Patent number: 9714429Abstract: This invention is in the field of plant biology and agriculture and relates to novel seed specific promoter regions. The present invention further provide methods of producing proteins and other products of interest and methods of controlling expression of nucleic acid sequences of interest using the seed specific promoter regions.Type: GrantFiled: January 27, 2015Date of Patent: July 25, 2017Assignee: ARKANSAS STATE UNIVERSITYInventors: Elizabeth Hood, Thomas Teoh
-
Publication number: 20150211014Abstract: This invention is in the field of plant biology and agriculture and relates to novel seed specific promoter regions. The present invention further provide methods of producing proteins and other products of interest and methods of controlling expression of nucleic acid sequences of interest using the seed specific promoter regions.Type: ApplicationFiled: January 27, 2015Publication date: July 30, 2015Inventors: Elizabeth Hood, Thomas Teoh
-
Patent number: 9028829Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.Type: GrantFiled: December 15, 2009Date of Patent: May 12, 2015Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Michael Chorny, Vladimir Muzykantov, Elizabeth Hood
-
Patent number: 8558058Abstract: Expression of recombinant polysaccharide degrading enzymes in plants is described. In one embodiment, expression of the enzyme is preferentially directed to the seed of the plant. Expression may also be preferentially targeted to specific locations within the plant cell. Expression of cellulases in corn is shown. The result is the capacity to produce polysaccharide degrading enzymes in plants at commercially acceptable levels in a reliable manner. Methods of using same in production of ethanol is also described, including use of the plant-produced enzymes in the ethanol production process.Type: GrantFiled: September 2, 2005Date of Patent: October 15, 2013Assignee: Applied Biotechnology InstituteInventors: Elizabeth Hood, John Howard
-
Publication number: 20130156792Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.Type: ApplicationFiled: December 15, 2009Publication date: June 20, 2013Applicants: The Trustees of the University of Pennsylvania, The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Michael Chorny, Vladimir Muzykantov, Elizabeth Hood
-
Patent number: 8435558Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound is presented. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. The niosomes may be administered to the subject via catheter. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored.Type: GrantFiled: July 18, 2011Date of Patent: May 7, 2013Assignee: University of South FloridaInventors: Elizabeth Hood, Joel A. Strom, Michael VanAuker
-
Patent number: 7981442Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored. Dye concentration in niosome samples decreased while the population and size distribution of the niosome remained largely unchanged.Type: GrantFiled: June 28, 2006Date of Patent: July 19, 2011Assignee: University of South FloridaInventors: Elizabeth Hood, Joel A. Strom, Michael VanAuker
-
Publication number: 20100260780Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.Type: ApplicationFiled: December 15, 2009Publication date: October 14, 2010Applicants: The Children's Hospital of Philadelphia, The Trustees of the University of PennsylvaniaInventors: Robert J. Levy, Michael Chorny, Vladimir Muzykantov, Elizabeth Hood
-
Patent number: 7541515Abstract: Increased expression of heterologous proteins in a plant is achieved by introducing the nucleotide sequence encoding the heterologous protein into a plant that has high oil seed content compared to low oil seed and/or is introduced into a plant having reduced alcohol soluble proteins in the endosperm. The nucleotide sequence may be introduced by direct transformation into the plant, or by direct transformation into another plant, and crossing with the high oil plant or plant have reduced levels of alcohol soluble protein in the endosperm. Further, the nucleotide sequences may be introduced into one or both of the high oil plant and the plant having reduced levels of alcohol soluble proteins, and the plants may be crossed to result in a progeny having even further increased expression levels of the heterologous protein.Type: GrantFiled: September 23, 2002Date of Patent: June 2, 2009Assignee: ProdiGene, Inc.Inventors: Elizabeth Hood, John Howard, Donna Delaney
-
Publication number: 20080050445Abstract: Taught herein is a drug-delivery system that includes encapsulating a therapeutic drug in a nanoparticle vesicle that is then embedded into a hydrogel network. The system allows for enhanced, two-fold control over the release rate of the drug. This technology will be particularly advantageous in treating malignant cancer cells such as those found in the brain. The invention will allow for decreased side effects and increased survival time in patients. This invention opens the door to other technological applications that require controlled release of chemical substances.Type: ApplicationFiled: April 19, 2007Publication date: February 28, 2008Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Norma Alcantar, Kristina Dearborn, Michael VanAuker, Ryan Toomey, Elizabeth Hood
-
Publication number: 20070172520Abstract: An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a functionalized membrane constituent. In a particular embodiment the functionalized membrane constituent is polyoxyethylene sorbitan monostearate functionalized with cyanuric chloride. The niosomes of this invention thus provide a composition that enhances internalization or retention of the bioactive agent of the niosome into the cytoplasm of the cells of the target tissue by providing a high degree of target specificity. Furthermore, the membrane vesicle enhances the life of the therapeutic agent by preventing its degradation in the extracellular environment, while exhibiting lower toxicity than can occur with some liposomes.Type: ApplicationFiled: November 20, 2006Publication date: July 26, 2007Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Michael VanAuker, Anna Plaas, Elizabeth Hood
-
Publication number: 20060292211Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored. Dye concentration in niosome samples decreased while the population and size distribution of the niosome remained largely unchanged.Type: ApplicationFiled: June 28, 2006Publication date: December 28, 2006Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Elizabeth Hood, Joel Strom, Michael VanAuker
-
Patent number: 7067726Abstract: Expression of a recombinant manganese-dependent peroxidase in plants is described. Methods for the recovery of transgenic corn seeds that express high levels of functional manganese-dependent peroxidase are also provided. Manganese-dependent peroxidase vectors are engineered to contain sequences directing seed-preferred expression as well as sequences for cell wall-targeted localization.Type: GrantFiled: June 6, 2003Date of Patent: June 27, 2006Assignees: Prodi Gene, Inc., Geneucor International, Inc.Inventors: Elizabeth Hood, John Howard, Richard Clough, Kameshwari Pappu
-
Patent number: 7049484Abstract: Production of proteases in plants is set forth, whereby heterologous DNA encoding the protease is introduced into the plant and expression of the protein achieved. By such methods, expression is achieved in plants wherein the plant cell is not damaged, the protein can be recovered without contamination by other proteases, and can be expressed at levels such that commercial production of the enzyme is obtained. Expression levels can be at 0.1% of total soluble protein of the plant, or higher.Type: GrantFiled: September 4, 2003Date of Patent: May 23, 2006Assignee: Prodi Gene, Inc.Inventors: John A. Howard, Elizabeth Hood
-
Publication number: 20060026715Abstract: Expression of recombinant polysaccharide degrading enzymes in plants is described. In one embodiment, expression of the enzyme is preferentially directed to the seed of the plant. Expression may also be preferentially targeted to specific locations within the plant cell. Expression of cellulases in corn is shown. The result is the capacity to produce polysaccharide degrading enzymes in plants at commercially acceptable levels in a reliable manner. Methods of using same in production of ethanol is also described, including use of the plant-produced enzymes in the ethanol production process.Type: ApplicationFiled: September 2, 2005Publication date: February 2, 2006Applicant: Applied Biotechnology Institute, LLC.Inventors: Elizabeth Hood, John Howard
-
Publication number: 20060015971Abstract: Production of proteases in plants is set forth, whereby heterologous DNA encoding the protease is introduced into the plant and expression of the protein achieved. By such methods, expression is achieved in plants wherein the plant cell is not damaged, the protein can be recovered without contamination by other proteases, and can be expressed at levels such that commercial production of the enzyme is obtained. Expression levels can be at 0.1% of total soluble protein of the plant, or higher.Type: ApplicationFiled: September 14, 2005Publication date: January 19, 2006Applicant: ProdiGene, Inc.Inventors: John Howard, Elizabeth Hood
-
Patent number: 6800792Abstract: Expression of laccase in plants at commercial levels of production is provided. The laccase gene is preferably operably linked with promoter sequences preferentially directing expression of laccase to the seed of the plant, and may additionally include sequences directing expression to the plant cell wall. Methods of improving the process of introducing DNA into plants via Agrobacterium are also provided.Type: GrantFiled: March 12, 2001Date of Patent: October 5, 2004Assignees: ProdiGene Inc., Genencor International, Inc.Inventors: John A. Howard, Elizabeth Hood, Joseph Jilka
-
Publication number: 20040049812Abstract: Production of proteases in plants is set forth, whereby heterologous DNA encoding the protease is introduced into the plant and expression of the protein achieved. By such methods, expression is achieved in plants wherein the plant cell is not damaged, the protein can be recovered without contamination by other proteases, and can be expressed at levels such that commercial production of the enzyme is obtained. Expression levels can be at 0.1% of total soluble protein of the plant, or higher.Type: ApplicationFiled: September 4, 2003Publication date: March 11, 2004Inventors: John A. Howard, Elizabeth Hood
-
Publication number: 20040010820Abstract: Expression of a recombinant manganese-dependent peroxidase in plants is described. Methods for the recovery of transgenic corn seeds that express high levels of functional manganese-dependent peroxidase are also provided. Manganese-dependent peroxidase vectors are engineered to contain sequences directing seed-preferred expression as well as sequences for cell wall-targeted localization.Type: ApplicationFiled: June 6, 2003Publication date: January 15, 2004Inventors: Elizabeth Hood, John Howard, Richard Clough, Kameshwari Pappu